Revenue
2021
2022
2023
2024
2025
ARS Pharmaceuticals, Inc. (SPRY)
Price$5.62Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30,000 | $1.3M | $5.5M | — |
| Gross profit | $63.9M | $88.2M | $30,000 | — | — | — |
| Gross margin | 75.77% | 98.90% | 100.00% | — | — | — |
| Research & development | $13.2M | $19.6M | $20.3M | $18.4M | $20.3M | $24.6M |
| Operating expenses | $263.7M | $92.2M | $67.5M | $36.8M | $25.0M | $32.9M |
| Operating income | −$179.4M | −$3.1M | −$67.5M | −$35.5M | −$19.5M | −$32.9M |
| Operating margin | −212.92% | −3.46% | −225,066.67% | −2,698.78% | −353.32% | — |
| EBITDA | −$178.1M | −$3.0M | −$67.4M | −$35.2M | −$19.2M | −$32.3M |
| EBITDA margin | −211.30% | −3.37% | −224,733.33% | −2,674.54% | −349.46% | — |
| Net income | −$171.3M | $8.0M | −$54.4M | −$34.7M | −$20.2M | −$32.9M |
| Net profit margin | −203.25% | 8.97% | −181,216.67% | −2,635.41% | −367.65% | — |
| Basic EPSper basic share | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 | -$11.33 |
| Diluted EPSper diluted share | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 | -$11.33 |
Owners
Reported shareholders
10.92%of listed shares
RA CAPITAL MANAGEMENT, L.P.10.86M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 10.92%10.86M shares |
Rubric Capital Management LP | 8.59%8.54M shares |
ORBIMED ADVISORS LLC | 8.34%8.29M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 7.55%7.5M shares |
BlackRock, Inc. | 5.34%5.31M shares |
Tyro Capital Management LLC | 4.48%4.46M shares |
Aberdeen Group plc | 4.19%4.17M shares |
SR One Capital Management, LP | 4.04%4.01M shares |
STATE STREET CORP | 3.75%3.73M shares |
Capital World Investors | 2.77%2.75M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.57%2.55M shares |
MILLENNIUM MANAGEMENT LLC | 2.41%2.4M shares |
Janney Montgomery Scott LLC | 2.08%2.06M shares |
UBS Group AG | 1.95%1.94M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.71%1.7M shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.61%1.6M shares |
GENERAL AMERICAN INVESTORS CO INC | 1.14%1.13M shares |
Third Point LLC | 1.01%1M shares |
PEREGRINE CAPITAL MANAGEMENT LLC | 0.68%672.14K shares |
Tejara Capital Ltd | 0.61%607.04K shares |
Percentages use 99.44M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 · 10b5-1 | Karas EricChief Commercial Officer | SellCommon Stock | 25.0K | $10.00 | $250.0K | 12.2K |
| Jun 12, 2026Form 4 · 10b5-1 | Fitzpatrick Alexander AChief Legal Officer | SellCommon Stock | 3.4K | $10.00 | $33.5K | 90.9K |
| Nov 13, 2025Form 4 | Dorsey BrianChief Operating Officer | SellCommon Stock | 21.8K | $8.71 | $190.1K | 10.8K |
| Nov 12, 2025Form 4 | Chakma JustinChief Business Officer | SellCommon Stock | 136.4K | $8.86 | $1.21M | 0 |
| Nov 12, 2025Form 4 | Chakma JustinChief Business Officer | SellCommon Stock | 30.0K | $8.91 | $267.3K | 136.4K |